Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 37 kDa laminin receptor precursor (37LRP), also known as the immature laminin receptor or 37 kDa oncofetal antigen (OFA/iLRP), is a multifunctional protein encoded by the RPSA gene [1]. It exists in two main forms: a 37 kDa cytoplasmic precursor and a 67 kDa mature membrane-bound form (67LR), which acts as a high-affinity receptor for laminin in the extracellular matrix [2]. Beyond its role in cell adhesion and migration, the protein is an integral component of the 40S ribosomal subunit, where it facilitates protein synthesis and ribosome biogenesis [1]. In clinical oncology, this receptor is frequently overexpressed on the surface of various malignant cells, including breast, lung, and colon cancers, where it correlates with increased metastatic potential and poor patient prognosis [4]. It also serves as a critical entry receptor for several human pathogens, including the cellular prion protein (PrPc) and various viruses such as Dengue and Sindbis [3]. Therapeutic targeting of the receptor involves the use of monoclonal antibodies or small molecules like epigallocatechin gallate (EGCG) to inhibit its interaction with laminin or pathogens [4]. However, the ubiquitous nature of its ribosomal function presents a significant challenge for achieving high therapeutic selectivity [2].
Inhibition of laminin-receptor interaction and modulation of intracellular signaling pathways [2][4].
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 37 kDa laminin receptor precursor (RPSA) (RPSA).